News

Published on 25 Dec 2022 on Simply Wall St. via Yahoo Finance

Investors in Pliant Therapeutics (NASDAQ:PLRX) have made a return of 19% over the past year


Article preview image

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make more than that. For example, the Pliant Therapeutics, Inc. (NASDAQ:PLRX) share price is up 19% in the last 1 year, clearly besting the market decline of around 23% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Note that businesses generally develop over the long term, so the returns over the last year might not reflect a long term trend.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

Check out our latest analysis for Pliant Therapeutics

NASDAQ.PLRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnin...

Zacks via Yahoo Finance 7 Mar 2024

Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares

Keith Cummings, the CFO of Pliant Therapeutics Inc, sold 9,781 shares of the company on January 1...

GuruFocus.com via Yahoo Finance 22 Jan 2024

Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Pliant The...

Zacks via Yahoo Finance 10 Nov 2023

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pliant Therapeut...

Zacks via Yahoo Finance 7 Nov 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zac...

Zacks via Yahoo Finance 10 Aug 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zac...

Zacks via Yahoo Finance 10 May 2023

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consen...

Zacks via Yahoo Finance 4 May 2023

Pliant Therapeutics: Latest Financials Support Stable Investment In Future Growth (PLRX)

Pliant Therapeutics (NASDAQ:PLRX) is a clinical-stage biotech company that researches and develop...

Seeking Alpha 15 Mar 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.72 per share versus the Zac...

Zacks via Yahoo Finance 10 Mar 2023

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a favorite amongst institutional investors who own 58%

Key Insights Given the large stake in the stock by institutions, Pliant Therapeutics' stock price...

Simply Wall St. via Yahoo Finance 5 Mar 2023